Trajenta (TRA-gen-ta), a new gliptin for type 2 diabetes

Reps will be promoting Trajenta (TRA-gen-ta), a new gliptin for type 2 diabetes.

Trajenta (linagliptin) is a "me-too"...similar to Onglyza (saxagliptin) and Januvia (sitagliptin). These prolong incretin activity to stimulate insulin and reduce glucagon release.

Trajenta's only real claim to fame is that it's approved for patients with mild to moderate renal impairment.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote